Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VOR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Telitacicept | Generalized Myasthenia Gravis | Phase 3 · NCT06456580 | Active not recruiting |
| Allogeneic Anti-CD33 CAR T-cells VCAR33 | Leukemia, Myeloid, Acute | Phase 1/2 · NCT05984199 | Terminated |
| Tremtelectogene Empogeditemcel (VOR33) | Leukemia, Myeloid, Acute | Phase 1/2 · NCT04849910 | Terminated |
Also used in these trials (approved or third-party drugs, not VOR's own candidates): Gemtuzumab Ozogamicin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VOR holds $481.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.1M/quarter from operations, an estimated runway of 49.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on our current operating plan, we expect that our cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into early 2029.10-Q, Oct 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VOR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| ForGrowth III PA B.V. | 5%+ holder (13D) | 10,237,714 | 16.66% | 2025-12-18 |
| FMR LLC | Institution (13G, 5%+) | 6,318,525 | 10.29% | 2026-09-30 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 5,676,370 | 9.24% | 2026-06-30 |
| Chen Yu | 5%+ holder (13G) | 5,673,078 | 9.23% | 2026-03-30 |
| RA CAPITAL MANAGEMENT, L.P. 10% owner · +7.96M options |
Insider | 4,503,382 | 7.33% | 2026-10-02 |
| Verve Capital Limited | 5%+ holder (13G) | 3,410,892 | 5.55% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 3,099,259 | 5.04% | 2026-06-30 |
| TCG Crossover GP II, LLC 10% owner |
Insider | 2,836,539 | 4.62% | 2026-03-30 |
| Reprogrammed Interchange LLC 10% owner |
Insider | 1,166,909 | 1.90% | 2025-10-17 |
| Peter Kolchinsky | Institution (13G, 5%+) | 810,671 | 1.32% | 2025-10-28 |
| Jeremy Brett Sokolove Chief Medical Officer |
Insider | 25,983 | 0.04% | 2026-11-02 |
Share count 61,434,344 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VOR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →